CCP
RDY icon

Corient Capital Partners’s Dr. Reddy's Laboratories RDY Stock Holding History

Corient Capital Partners’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$222K Hold
20,075
– – 0.02% 579
2022
Q2 		$222K Sell
20,075
-5,155
-20% -$56.1K 0.02% 590
2022
Q1 		$281K Buy
25,230
+2,530
+11% +$28.7K 0.02% 568
2021
Q4 		$297K Buy
22,700
+995
+5% +$12.5K 0.02% 520
2021
Q3 		$283K Buy
21,705
+4,055
+23% +$54K 0.02% 515
2021
Q2 		$259K Buy
+17,650
New +$247K 0.02% 533

Other funds holding RDY

Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Corient Capital Partners's RDY Position: Q3 2022 in Review

Corient Capital Partners held its Dr. Reddy's Laboratories (RDY) position steady in Q3 2022 at 20,075 shares worth $222K. The position accounts for 0.02% of the portfolio, ranked #579.

Corient Capital Partners first reported a position in RDY in Q2 2021 and has held it in 6 quarters since. The position peaked at $297K in Q4 2021. 150 funds tracked by Wall St. Rank hold RDY as of Q3 2022.

  • Corient Capital Partners held 20,075 shares of Dr. Reddy's Laboratories worth $222K as of Q3 2022.
  • Corient Capital Partners left its Dr. Reddy's Laboratories share count unchanged in Q3 2022.
  • Dr. Reddy's Laboratories made up 0.02% of Corient Capital Partners's portfolio in Q3 2022, its #579 holding.
  • Corient Capital Partners first reported a position in Dr. Reddy's Laboratories in Q2 2021 and has held it in 6 quarters since.
  • Corient Capital Partners's Dr. Reddy's Laboratories position peaked at $297K in Q4 2021.
  • 150 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.